Ascentage Pharma Group (AAPGV): Rasio rega marang prakiraan pendapatan
Ascentage Pharma Group delegates protein synthesis and early-stage testing to external contractors, focusing on developing therapies to combat oncology and age-related pathologies. The forward P/S multiple helps assess the stock value relative to future sales, with the value of 8.50 serving as the current indicator. Olverembatinib provides a stable cash flow, confirming the high commercial value of the company's patent portfolio.
Ascentage - rincian analitis lan metrik utama (AAPGV)
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi bursa:
- indikator nilai buku ekuitas:
- data liabilitas lan likuiditas perusahaan:
Utang marang Ekuitas Ascentage Pharma Group|AAPGV - Rasio utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Ascentage Pharma Group|AAPGV - Tanggungan utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Ascentage|AAPGV - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Ascentage Pharma|Rasio cepet ascentage.com
- rincian asil keuangan lan kelipatan valuasi:
AAPGV - Penghasilan resik perusahaan|Bathi mangsa ngarep Ascentage Pharma Group|AAPGV - Nilai perusahaan marang bathi resik|Rega marang bathi mangsa ngarep Ascentage Pharma Group Ltd|AAPGV - Rasio kapitalisasi marang bathi lan wutah|Pangali EV/EBITDA Ascentage|AAPGV - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) Ascentage Pharma|AAPGV - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan ascentage.com|AAPGV - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Ascentage Pharma Group
- data dodolan lan asil:
Analisis umum perusahaan:Ascentage Pharma AAPGV
Investments in elite apoptosis specialists and the large-scale expansion of laboratories at Ascentage Pharma Group (AAPGV) drive the high valuation of future developments. By analyzing the projected P/S trend, investors can discern market revenue expectations for the coming year, where the ratio of market capitalization to forecasted sales filters out price volatility, enabling a real-time assessment of the fundamental value of this high-tech biopharmaceutical asset.
Pesaing Ascentage Pharma Group
Multiplikator Forward P/S ONC (BeiGene)|Multiplikator Forward P/S Halozyme Therapeutics, Inc. HALO|RVMD - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Ascentage Pharma Corp AAPG|CGON: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan urogen.com|BCAX (Bicara Therapeutics) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Personalis Inc PSNL|Rasio rega marang prakiraan pendapatan Erasca Corp (ERAS)|Delcath Corp - Kapitalisasi marang prakiraan pendapatan|Y-mAbs Therapeutics - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake AURA (aurabiosciences.com)|Candel - Multiplikator Forward P/S|ARAY - Multiplikator Forward P/S|SLS: Multiplikator Forward P/S|Prakiraan rega marang pendapatan Actuate Therapeutics Inc ACTU|CTOR (Citius Oncology, Inc.) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep TuHURA HURA|Multiplikator forward rega marang pendapatan TARA (Protara Therapeutics, Inc.)|FATE (Fate Therapeutics Inc) - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Aadi Bioscience WHWK|TCRX (TScan Therapeutics Inc) - Rega mangsa ngarep marang pendapatan|Champions Oncology Corp - Multiplikator Forward P/S|Rega forward marang dodolan XBIT (XBiotech Inc.)|CVM: Multiplikator Forward P/S|OS Therapies Inc. (OSTX) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Radiopharm Theranostics Limited|ARTV: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Adlai Nortye Ltd. (ANL)|Multiplikator forward rega marang pendapatan verupharma.com VERU|Multiplikator Forward P/S TPST (Tempest Therapeutics, Inc.)|Multiplikator Forward P/S Xilio Therapeutics Inc XLO|RENB: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan MURA (Mural Oncology plc)|KAPA: Multiplikator Forward P/S|Prakiraan rega marang pendapatan OnKure Therapeutics OKUR|Rasio rega marang prakiraan pendapatan CytoMed Therapeutics Ltd|CRIS: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Apollomics, Inc. (APLM)|THAR - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Advanced Biomed - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S genprex.com GNPX|CLDI - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan SBFM|XBIO: Multiplikator Forward P/S|Salarius Pharma (SLRX) - Multiplikator Forward P/S|PPBT (Purple Biotech) - Multiplikator Forward P/S|Multiplikator Forward P/S AON|Rasio rega marang prakiraan pendapatan BeiGene (BGNE)|CKPT: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S ELEV (Elevation Oncology, Inc.)|Prakiraan rega marang pendapatan iCAD Inc.|IKNA: Multiplikator forward rega marang pendapatan|NTBL: Rasio rega marang prakiraan pendapatan|VIRX: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan MorphoSys Inc|NAYA (NAYA Bio) - Multiplikator Forward P/S
